Skip to main content

Heron Therapeutics Value Stock - Dividend - Research Selection

Heron Therapeutics

ISIN: US4277461020, WKN: A1XB6K

Market price date: 01.06.2021
Market price: 13,34 USD




Heron Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 02-03-2021
Cash flow
Net operating cash flow -184.820.000
Capital Expenditures -6.813.000
Free cash flow -191.632.992
Balance sheet
Total Equity 236.492.000
Liabilities & Shareholders equity 353.556.000
Income statement
Net income -227.278.000
Eps (diluted) -2,489
Diluted shares outstanding 91.310.000
Net sales/revenue 88.638.000

Fundamental ratios calculated on: 01-06-2021

Ratios
Key figures 01-06-2021
Cash flow
P/C -6,59
   
P/FC -6,36
Balance sheet
ROI-64,28
ROE66,89
Income statement
P/E-5,36
Div. Yield0,00%
P/B5,15
P/S13,74


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolHRTX
Market Capitalization1.218.075.392,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2014-01-13,1.0000/20.0000; 2007-05-25,1.0000/4.0000
Internetwww.appharma.com


Description of the company

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.appharma.com